Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area

Vaccine
Philip BejonAdrian V S Hill

Abstract

In a phase 1 trial, 22 children in a malaria endemic area were immunised with candidate malaria vaccination regimes. The regimes used two recombinant viral vectors, attenuated fowlpox strain FP9 and modified vaccinia virus Ankara (MVA). Both encoded the pre-erythrocytic malaria antigen construct ME-TRAP. Strong T cell responses were detected by both ex vivo and cultured ELISpot assays. Data from phase 1 trials in adults on anti-vector responses raised by FP9 is presented. These responses partially cross-reacted with MVA, and detectably reduced the immunogenicity of vaccination with MVA. This prompted the comparison of half dose and full dose FP9 priming vaccinations in children. Regimes using half dose FP9 priming tended to be more immunogenic than full dose. The potential for enhanced immunogenicity with half doses of priming vectors warrants further investigation, and larger studies to determine protection against malaria in children are required.

References

Nov 14, 1997·Nature Biotechnology·S C GilbertA V Hill
Oct 11, 2003·The Journal of Infectious Diseases·Vasee S MoorthyAdrian V S Hill
May 1, 1997·Parasitology Today·D L Doolan, S L Hoffman
Mar 23, 2005·Proceedings of the National Academy of Sciences of the United States of America·Daniel P WebsterAdrian V S Hill
Aug 24, 2007·Clinical and Vaccine Immunology : CVI·Kevin L KaremInger K Damon
Mar 22, 2008·The Journal of Allergy and Clinical Immunology·Andrew GodkinRobert I Lechler

❮ Previous
Next ❯

Citations

Sep 20, 2008·PLoS Pathogens·Martha A HutchensGary D Luker
Jan 11, 2012·Malaria Journal·Lauren SchwartzVasee S Moorthy
Feb 8, 2013·Nature Medicine·Eleanor M Riley, V Ann Stewart
Apr 9, 2015·Viruses·Lucas Sánchez-SampedroMariano Esteban
May 1, 2008·Expert Review of Vaccines·Rajeev K TyagiAbhinav Mehta
Oct 31, 2013·Expert Review of Vaccines·Carmen Elena GómezMariano Esteban
Mar 26, 2013·Vaccine·Matthew G Cottingham, Miles W Carroll
May 9, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Rajeev K TyagiTejram Sahu
May 22, 2007·Trends in Parasitology·D Gray HeppnerAdrian J F Luty
Jan 1, 2014·Immunologic Research·Nathaniel D LambertGregory A Poland
Nov 3, 2011·Immunology·Sarah C Gilbert
Aug 18, 2006·Vaccine·Shengqiang LiFilip Dubovsky
Oct 19, 2006·Vaccine·Marc P GirardMarie Paule Kieny
May 6, 2010·PLoS Pathogens·Diana S Hansen, Louis Schofield
Oct 29, 2020·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Christiane Sigrid Eberhardt, Claire-Anne Siegrist

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.